266 related articles for article (PubMed ID: 36342120)
21. Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.
Rubin DT; Torres J; Regueiro M; Reinisch W; Prideaux L; Kotze PG; Tan FH; Gardiner S; Mundayat R; Cadatal MJ; Ng SC
Crohns Colitis 360; 2024 Jan; 6(1):otae004. PubMed ID: 38425446
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
Hudesman DP; Torres J; Salese L; Woolcott JC; Mundayat R; Su C; Mosli MH; Allegretti JR
Patient; 2023 Mar; 16(2):95-103. PubMed ID: 36336750
[TBL] [Abstract][Full Text] [Related]
23. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.
Dubinsky MC; Magro F; Steinwurz F; Hudesman DP; Kinnucan JA; Ungaro RC; Neurath MF; Kulisek N; Paulissen J; Su C; Ponce de Leon D; Regueiro M
Inflamm Bowel Dis; 2023 Jan; 29(1):51-61. PubMed ID: 35380664
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Sandborn WJ; Lawendy N; Danese S; Su C; Loftus EV; Hart A; Dotan I; Damião AOMC; Judd DT; Guo X; Modesto I; Wang W; Panés J
Aliment Pharmacol Ther; 2022 Feb; 55(4):464-478. PubMed ID: 34854095
[TBL] [Abstract][Full Text] [Related]
25. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Quirk D; Wang W; Nduaka CI; Mukherjee A; Su C; Sands BE
Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1821-1830.e3. PubMed ID: 33127596
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
[TBL] [Abstract][Full Text] [Related]
29. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Farraye FA; Qazi T; Kotze PG; Moore GT; Mundayat R; Lawendy N; Sharma PP; Judd DT
Aliment Pharmacol Ther; 2021 Aug; 54(4):429-440. PubMed ID: 34165201
[TBL] [Abstract][Full Text] [Related]
30. Presence of risk factors associated with colectomy among patients with ulcerative colitis: a
Rubin DT; Salese L; Cohen M; Kotze PG; Woolcott JC; Su C; Mundayat R; Paulissen J; Torres J; Long MD
Therap Adv Gastroenterol; 2023; 16():17562848231189122. PubMed ID: 37560161
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
Panés J; Vermeire S; Dubinsky MC; Loftus EV; Lawendy N; Wang W; Salese L; Su C; Modesto I; Guo X; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1852-1863. PubMed ID: 33884415
[TBL] [Abstract][Full Text] [Related]
32. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294
[TBL] [Abstract][Full Text] [Related]
33. Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
Schreiber S; Rubin DT; Ng SC; Peyrin-Biroulet L; Danese S; Modesto I; Guo X; Su C; Kwok KK; Jo H; Chen Y; Yndestad A; Reinisch W; Dubinsky MC
J Crohns Colitis; 2023 Nov; 17(11):1761-1770. PubMed ID: 37402275
[TBL] [Abstract][Full Text] [Related]
34. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
Biedermann L; Dubinsky MC; Vermeire S; Fellmann M; Gardiner S; Hur P; Mundayat R; Panés J; Rubin DT
Inflamm Bowel Dis; 2023 Sep; 29(9):1370-1379. PubMed ID: 36242764
[TBL] [Abstract][Full Text] [Related]
35. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
Lee SD; Allegretti JR; Steinwurz F; Connelly SB; Lawendy N; Paulissen J; Gecse KB
BMC Gastroenterol; 2023 Feb; 23(1):34. PubMed ID: 36755231
[TBL] [Abstract][Full Text] [Related]
36. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
Winthrop KL; Yndestad A; Henrohn D; Danese S; Marsal S; Galindo M; Woolcott JC; Jo H; Kwok K; Shapiro AB; Jones TV; Diehl A; Su C; Panés J; Cohen SB
Rheumatol Ther; 2023 Apr; 10(2):357-373. PubMed ID: 36526796
[TBL] [Abstract][Full Text] [Related]
37. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
[TBL] [Abstract][Full Text] [Related]
38. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Sands BE; Colombel JF; Ha C; Farnier M; Armuzzi A; Quirk D; Friedman GS; Kwok K; Salese L; Su C; Taub PR
Inflamm Bowel Dis; 2021 May; 27(6):797-808. PubMed ID: 32870265
[TBL] [Abstract][Full Text] [Related]
39. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Mukherjee A; Tsuchiwata S; Nicholas T; Cook JA; Modesto I; Su C; D'Haens GR; Sandborn WJ
Clin Pharmacol Ther; 2022 Jul; 112(1):90-100. PubMed ID: 35380740
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
Suzuki Y; Watanabe M; Matsui T; Motoya S; Hisamatsu T; Yuasa H; Tabira J; Isogawa N; Tsuchiwata S; Arai S; Hibi T
Inflamm Intest Dis; 2019 Oct; 4(4):131-143. PubMed ID: 31768386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
